Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Merck & Company Inc. | Calderasib (MK-1084) with KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph) - (KANDLELIT-007) | KRAS G12C-mutant, advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) | Phase 3 | Enrollment Initiation | Intravenous | Oncology |
| Merck & Company Inc. | Patritumab Deruxtecan (HER3-DXd) - (HERTHENA-Breast04) | Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer | Phase 3 | Enrollment Initiation | Intravenous | Oncology |
| Merck & Company Inc. | WELIREG (belzutifan) and LENVIMA (lenvatinib) - (LITESPARK-011) | Advanced Renal Cell Carcinoma | Phase 3 | Data Released | Oral | Oncology |
| Merck & Company Inc. | KEYTRUDA (pembrolizumab) plus Padcev (enfortumab vedotin-ejfv) - (KEYNOTE-905/EV-303) | Muscle-Invasive Bladder Cancer | Phase 3 | Data Released | Intravenous | Oncology |
| Merck & Company Inc. | CAPVAXIVE (Pneumococcal 21-valent Conjugate Vaccine) - (STRIDE-13) | Pneumococcal Disease | Phase 3 | Data Released | Intramuscular | Respiratory |
| Merck & Company Inc. | VERQUVO (vericiguat) - (VICTOR) | Chronic Heart Failure and Reduced Ejection Fraction | Phase 3 | Data Released | Oral | Cardiology |
| Merck & Company Inc. | Ifinatamab deruxtecan (DS-7300) - (IDeate-Prostate01) | Prostate Cancer | Phase 3 | Ongoing | Intravenous | Oncology |
| Merck & Company Inc. | V181 - (MOBILIZE-1) | Dengue virus | Phase 3 | Enrollment Initiation | Intramuscular | N/A |
